Source:http://linkedlifedata.com/resource/pubmed/id/11849213
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2002-3-7
|
pubmed:abstractText |
Between January 1985 and December 1992, 104 consecutive patients with symptomatic myelofibrosis with myeloid metaplasia (MMM) [splenic enlargement >5 cm and/or transfusional requirement or Hb < 10 g/dl and/or white blood cell (WBC) count >20 x 10(9)/l and/or platelets >1.0 x 10(9)/l] received low-dose Melphalan (2.5 mg/3 times/week) to evaluate the efficacy and toxicity of this approach. Among 99 evaluable patients, 66 (66.7%) achieved a response after a median time of 6.7 months: 26 (26.3%) had a normalization of all clinical and haematological parameters (complete response, CR) and 40 (40.4%) showed an improvement >50% (partial response, PR). Thirty-three patients (33.3%) were resistant. Reversible haematological toxicity was the most common complication. Median durations of CR and PR were 28.4 and 26 months respectively: median survival of CR + PR patients was 71.2 months (95%CI: 33.8-108.7) versus 36.5 months (95%CI: 24.5-48.5) for the non-responders (log-rank test, P =0.002). In the multivariate analysis, the following variables were significantly associated with a shorter survival: anaemia [hazard risk (HR) = 2.7], WBC count >20 x 10(9)/l (HR = 2.4) and not achieving any type of response, either partial or complete (HR = 3.9). In conclusion, Melphalan could be a promising first-line option for MMM patients with clinical or haematological symptoms requiring treatment.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0007-1048
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
116
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
576-81
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:11849213-Adult,
pubmed-meshheading:11849213-Aged,
pubmed-meshheading:11849213-Aged, 80 and over,
pubmed-meshheading:11849213-Anemia,
pubmed-meshheading:11849213-Antineoplastic Agents, Alkylating,
pubmed-meshheading:11849213-Female,
pubmed-meshheading:11849213-Follow-Up Studies,
pubmed-meshheading:11849213-Humans,
pubmed-meshheading:11849213-Leukocyte Count,
pubmed-meshheading:11849213-Male,
pubmed-meshheading:11849213-Melphalan,
pubmed-meshheading:11849213-Middle Aged,
pubmed-meshheading:11849213-Primary Myelofibrosis,
pubmed-meshheading:11849213-Prognosis,
pubmed-meshheading:11849213-Survival Rate,
pubmed-meshheading:11849213-Treatment Outcome
|
pubmed:year |
2002
|
pubmed:articleTitle |
Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.
|
pubmed:affiliation |
Ematologia, Istituto Regina Elena, Rome, Italy. rob.lati@libero.it
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|